HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia.

Abstract
Two separate studies were carried out with acipimox, a new antilipolytic agent with long-lasting activity. First, in a randomized, double-blind, cross-over study a dose of 750 mg/day of acipimox versus placebo was employed for 60 days in 11 patients with type IV hyperlipoproteinemia. Mean plasma triglyceride levels were reduced after acipimox compared to placebo (434 +/- 60 vs 777 +/- 224 mg/dl, P less than 0.01). Serum total cholesterol fell also significantly after acipimox compared to placebo. No significant alteration was observed in the HDL2/HDL3 ratio or in the concentration or composition of the HDL subfractions. Six patients with severe hypertriglyceridemia (2 type IV and 4 type V) and low lipoprotein lipase (LPL) activity took part in a second, open study, lasting for 9 months. Acipimox was given at a dose of 750 mg/day for the first 6 months and 1200 mg/day for the last period. The response of serum total and VLDL triglycerides was inconsistent. HDL cholesterol was significantly raised (+33.3%) after 9 months of treatment due to changes of HDL2 and HDL3 cholesterol, phospholipid and protein concentrations. LPL activity was markedly reduced in adipose tissue at 9 months. No significant changes occurred in postheparin plasma LPL activity. In contrast, hepatic lipase activity showed a reduction of about 25% from 6 months of treatment onwards.
AuthorsM R Taskinen, E A Nikkilä
JournalAtherosclerosis (Atherosclerosis) Vol. 69 Issue 2-3 Pg. 249-55 (Feb 1988) ISSN: 0021-9150 [Print] Ireland
PMID3279968 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Cholesterol, HDL
  • Hypolipidemic Agents
  • Lipoproteins, HDL
  • Phospholipids
  • Pyrazines
  • Triglycerides
  • Lipase
  • Lipoprotein Lipase
  • acipimox
Topics
  • Adult
  • Cholesterol, HDL (blood)
  • Clinical Trials as Topic
  • Double-Blind Method
  • Humans
  • Hyperlipoproteinemia Type IV (drug therapy)
  • Hyperlipoproteinemia Type V (drug therapy)
  • Hypolipidemic Agents (therapeutic use)
  • Lipase (blood)
  • Lipoprotein Lipase (blood)
  • Lipoproteins, HDL (blood)
  • Male
  • Middle Aged
  • Phospholipids (blood)
  • Pyrazines (therapeutic use)
  • Random Allocation
  • Triglycerides (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: